# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Oppenheimer analyst Suraj Kalia initiates coverage on TriSalus Life Sciences (NASDAQ:TLSI) with a Outperform rating and anno...
TriSalus Life Sciences (NASDAQ:TLSI) reported quarterly losses of $(0.21) per share which beat the analyst consensus estimate o...
Canaccord Genuity analyst William Plovanic maintains TriSalus Life Sciences (NASDAQ:TLSI) with a Buy and maintains $12 price...
TriSalus Life Sciences, Inc. (NASDAQ:TLSI), an oncology company integrating its novel Pressure Enabled Drug Delivery™ (PEDD™) t...
Canaccord Genuity analyst William Plovanic initiates coverage on TriSalus Life Sciences (NASDAQ:TLSI) with a Buy rating and ...